---
figid: PMC3627370__nihms449846f1
figlink: /pmc/articles/PMC3627370/figure/F1/
number: Fig. 1
caption: The role of NAMPT in mammalian NAD metabolism. (a) The salvage of NAD (red
  labels) is predominantly by NAMPT, the rate-limiting formation of NMN from NAM and
  α-D-5-phosphoribosyl 1-pyrophosphate (PRPP). NMN is converted to NAD by three isoforms
  of NMN adenylyltransferase (NMNAT, EC 2.7.7.1). NMN can also arise from phosphorylation
  of nicotinamide riboside (NR), an additional salvageable NAD precursor (nicotinamide
  riboside kinase; NRK, EC 2.7.1.22). Other ways to generate NAD include its salvage
  from NA and the de novo synthesis from L-Trp. The NAD pool needs constant replenishment
  because of NAD use (blue labels). Lifespan extension may be promoted by SIRT1 through
  FOXO/p53 deacetylation. Stress stimuli (IL-1β) enhances NAD production through NAMPT
  over-expression. Likewise, STAT 3 (through an IL-6 signaling pathway), NF-κB and
  TNFα, up-regulate nampt (red DNA). PGE2 is implicated in arthritis (via mPGES-1
  up-regulation). FK866 and GMX17778 inhibit NAMPT. (b) The pyrophosphorolysis reaction
  catalyzed by NAMPT
pmcid: PMC3627370
papertitle: Recycling nicotinamide. The transition-state structure of human nicotinamide
  phosphoribosyltransferase.
reftext: Emmanuel S. Burgos, et al. J Am Chem Soc. ;135(9):3485-3493.
pmc_ranked_result_index: '44386'
pathway_score: 0.9076082
filename: nihms449846f1.jpg
figtitle: NAMPT in mammalian NAD metabolism
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3627370__nihms449846f1.html
  '@type': Dataset
  description: The role of NAMPT in mammalian NAD metabolism. (a) The salvage of NAD
    (red labels) is predominantly by NAMPT, the rate-limiting formation of NMN from
    NAM and α-D-5-phosphoribosyl 1-pyrophosphate (PRPP). NMN is converted to NAD by
    three isoforms of NMN adenylyltransferase (NMNAT, EC 2.7.7.1). NMN can also arise
    from phosphorylation of nicotinamide riboside (NR), an additional salvageable
    NAD precursor (nicotinamide riboside kinase; NRK, EC 2.7.1.22). Other ways to
    generate NAD include its salvage from NA and the de novo synthesis from L-Trp.
    The NAD pool needs constant replenishment because of NAD use (blue labels). Lifespan
    extension may be promoted by SIRT1 through FOXO/p53 deacetylation. Stress stimuli
    (IL-1β) enhances NAD production through NAMPT over-expression. Likewise, STAT
    3 (through an IL-6 signaling pathway), NF-κB and TNFα, up-regulate nampt (red
    DNA). PGE2 is implicated in arthritis (via mPGES-1 up-regulation). FK866 and GMX17778
    inhibit NAMPT. (b) The pyrophosphorolysis reaction catalyzed by NAMPT
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PARP8
  - NAMPT
  - TP53
  - TNKS2
  - PARP9
  - PARP14
  - IL6
  - PARP6
  - MUC7
  - PARP11
  - PARP12
  - TNF
  - PARP16
  - FOXO6
  - NFKB1
  - FOXO4
  - CD38
  - NMNAT1
  - PARP10
  - TIPARP
  - PARP15
  - FOXO3
  - PARP2
  - NRK
  - PARP1
  - TNKS
  - FOXO1
  - PARP4
  - PARP3
  - GMX1778
  - Trp
genes:
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP8
  entrez: '79668'
- word: nampt
  symbol: NAMPT
  source: hgnc_symbol
  hgnc_symbol: NAMPT
  entrez: '10135'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS2
  entrez: '80351'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP9
  entrez: '83666'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP14
  entrez: '54625'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP6
  entrez: '56965'
- word: Mg2+
  symbol: MG2
  source: hgnc_alias_symbol
  hgnc_symbol: MUC7
  entrez: '4589'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP11
  entrez: '57097'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP12
  entrez: '64761'
- word: NF-KB,TNFa
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP16
  entrez: '54956'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: NF-KB,
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: CD38
  symbol: CD38
  source: hgnc_symbol
  hgnc_symbol: CD38
  entrez: '952'
- word: (NMNAT
  symbol: NMNAT
  source: hgnc_alias_symbol
  hgnc_symbol: NMNAT1
  entrez: '64802'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP10
  entrez: '84875'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TIPARP
  entrez: '25976'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP15
  entrez: '165631'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP2
  entrez: '10038'
- word: NRK
  symbol: NRK
  source: hgnc_symbol
  hgnc_symbol: NRK
  entrez: '203447'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP1
  entrez: '142'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS
  entrez: '8658'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP4
  entrez: '143'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP3
  entrez: '10039'
chemicals:
- word: GMX1778
  source: MESH
  identifier: C401312
- word: Trp
  source: MESH
  identifier: D014364
diseases: []
---
